Citius Pharmaceuticals, Inc. 8-K

What Happened

• On April 29, 2026 Citius Pharmaceuticals, Inc. (CTXR) filed a Form 8-K reporting that it closed a registered direct offering of common stock and a concurrent private placement of pre‑funded warrants, common warrants and placement agent warrants (as previously disclosed).
• The filing also reports that Citius’ majority‑owned subsidiary, Citius Oncology, Inc. (Nasdaq: CTOR), issued a press release on April 29, 2026 announcing the initial shipment of LYMPHIR™ (denileukin diftitox‑cxdl) to Europe through a regional distribution partner. The press release is included as Exhibit 99.1 to the 8‑K.

Key Details

• Filing date: April 29, 2026 (Form 8‑K).
• Equity transactions: closed a registered direct offering of common stock plus a concurrent private placement of pre‑funded warrants, common warrants and placement agent warrants (no dollar amounts disclosed in this 8‑K).
• Subsidiary: Citius Oncology, Inc. (Nasdaq: CTOR).
• Product/shipment: initial shipment of LYMPHIR™ (denileukin diftitox‑cxdl) to Europe via a regional distribution partner; press release attached as Exhibit 99.1.

Why It Matters

• Equity transactions: the offerings described may affect share count and potential dilution for CTXR shareholders; investors should review prior disclosures for terms, investor allocations and proceeds.
• Commercial progress: the initial shipment of LYMPHIR to Europe is a commercialization milestone for the company’s oncology subsidiary and could be a step toward future revenue from the product in that region.
• Next steps: the 8‑K does not provide financial results or offering proceeds; investors should watch for additional SEC filings or company announcements with financial details or commercial updates.